ATRIAL FIBRILLATION FOLLOWING CARDIAC SURGERY: PATHOPHYSIOLOGY AND PREVENTION TECHNIQUES (part 2)

Atrial fibrillation is one of the most frequent complications occurring after cardiac surgery. This problem became especially crucial for the last decade due to brisk growth in cardiac surgery and surgeries in the patients with high risks. Post-operative atrial fibrillation confidently increases the risk of mortality and associated complications. This disease is diagnosed first of all by ECG tests. At present in order to detect atrial fibrillation early European Heart Rhythm Association (EHRA) recommends using technologies of continuous rhythm monitoring - implanted cardiac monitors. Currently there are two main approaches to management of postoperative atrial fibrillation. These are the strategies of rhythm monitoring and heart rate monitoring supplemented anti-thrombotic therapy. A wide range of drugs is used for anti-thrombotic therapy in the patients undergoing cardiac surgery. Effective management of post-operative atrial fibrillation in those undergoing cardiac surgery is to consider clinical status of the patient, concurrent diseases and risk of stroke and hemorrhage.

1. REFERENCES

2. AFFIRM. First Antiarrhythmic Drug Substudy Investigators: Maintenance of sinus rhythm in patients with atrial fibrillation: An AFFIRM substudy.

3. Almassi G.H., Schowalter T., Nicolosi A.C. et al: Atrial fibrillation after cardiac surgery: A major morbid event? Surg., 1997, vol. 226, pp. 501-511.

4. Aranki S.F., Shaw D.P., Adams D.H. et al. Predictors of atrial fibrillation after coronary artery surgery. Current trends and impact on hospital resources. Circulation, 1996, vol. 94, pp. 390-397.

5. Auer J., Weber T., Berent R. et al. Postoperative atrial fibrillation independently predicts prolongation of hospital stay after cardiac surgery. J. Cardiovasc. Surg. (Torino), 2005, vol. 46, pp. 583-588.

6. Brignole M., Vardas P., Hoffman E. et al. Indications for the use of diagnostic implantable and external ECG loop recorders. Europace, 2009, vol. 11, pp. 671-687.

7. Chen-Scarabelli C., Scarabelli T.M., Ellenbogen K.A. et al. Devicedetected atrial fibrillation: What to do with asymptomatic patients? J. Am. Coll. Cardiol., 2015, vol. 5, pp. 281-294.

8. Connolly S.J., Camm A.J., Halperin J.L. et al. Dronedarone in high-risk permanent atrial fibrillation. N. Engl. J. Med., 2011, vol. 365, pp. 2268-2276.

9. Dagres N., Kottkamp H., Piorkowski C. et al. Influence of the duration of Holter monitoring on the detection of arrhythmia recurrences after catheter ablation of atrial fibrillation: Implications for patient follow-up. Int. J. Cardiol., 2010, vol. 139, pp. 305-306.

10. de Vos C.B., Pisters R., Nieuwlaat R. et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J. Am. Coll. Cardiol., 2010, vol. 55, pp. 725-731.

11. Eikelboom J.W., Connolly S.J., Brueckmann M. et al. Dabigatran versus warfarin in patients with mechanical heart valves. N. Engl. J. Med., 2013, vol. 369, pp. 1206-1214.

12. El-Chami M.F., Kilgo P., Thourani V. et al. New-onset atrial fibrillation predicts long-term mortality after coronary artery bypass graft. J. Am. Coll. Cardiol., 2010, vol. 55, pp. 370-376.

13. Fang M.C., Go A.S., Chang Y. et al. A new risk scheme to predict warfarin– associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J. Am. Coll. Cardiol., 2011, vol. 58, pp. 395-401.

14. Freemantle N., Lafuente-Lafuente C., Mitchell S. et al. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace, 2011, vol. 13, pp. 329-345.

15. Frendl G., Sodickson A.C., Chung M.K. et al. 2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. J. Thorac. Cardiovasc. Surg., 2014, vol. 148, pp. 153-193.

16. Gage B.F., Waterman A.D., Shannon W. et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA, 2001, vol. 285, pp. 2864-2870.

17. Glotzer T.V., Daoud E.G., Wyse D.G. et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: The TRENDS study. Circ. Arrhythm. Electrophysiol., 2009, vol. 2, pp. 474-480.

18. Gutsche J.T., Riha H., Patel P. et al. Major themes for 2013 in cardiothoracic and vascular anaesthesia and intensive care. Heart Lung Vessel, 2014, vol. 6, pp. 79-87.

19. Hillis L.D., Smith P.K., Anderson J.L. et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice

20. Guidelines. Circulation, 2011, vol. 124, pp. e652–e735.

21. Hindricks G., Pokushalov E., Urbna L. et al. performance of a new leadless implantable cardiac monitor in detecting and quantifying atrial fibrillation results of the XPECT trial. Circ. Arrhythm. Electrophysiol., 2010, vol. 3, pp. 141-147.

22. Holmes D.R.Jr., Kar S., Price M.J. et al: Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J. Am. Coll. Cardiol., 2014, vol. 64, pp. 1-12.

23. January C.T., Wann L.S., Alpert J.S. et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation, 2014, vol. 130, pp. e199–е267.

24. Jideus L., Blomstrom P., Nilsson L. et al. Tachyarrhythmias and triggering factors for atrial fibrillation after coronary artery bypass operation. Ann. Thorac. Surg., 2000, vol. 69, pp. 1064-1069.

25. Klein A.L., Grimm R.A., Murray R.D. et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N. Engl. J. Med., 2001, vol. 344, pp. 1411-1420.

26. Køber L., Torp-Pedersen C., McMurray J.J. et al. Increased mortality after dronedarone therapy for severe heart failure. N. Engl. J. Med., 2000, vol. 358, pp. 2678-2687.

27. Lee J.K., Klein G.J., Krahn A.D. et al. Rate-control versus conversion strategy in postoperative atrial fibrillation: A prospective, randomized pilot study. Am. Heart J., 2000, vol. 140, pp. 871-877.

28. Lip G.Y., Nieuwlaat R., Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest, 2010, vol. 137, pp. 263-272.

29. Lomivorotov V.V., Efremov S.M., Pokushalov E.A. et al. Randomized trial of fish oil infusion to prevent atrial fibrillation after cardiac surgery: data from an implantable continuous cardiac monitor. J. Cardiothorac. Vasc. Anesth., 2014, vol. 28, pp. 1278-1284.

30. Mitchell L.B. Incidence, timing and outcome of atrial tachyarrhythmias after cardiac surgery, In Steinberg JS (ed). Atrial Fibrillation After Cardiac Surgery. Norwell, MA: Kluwer Academic Publishers, 2000, pp. 37-50.

31. Mittal S., Ferrara M., Arshad A. et al. Heart Rhythm., 2013, vol. 10, no. 11, pp. 1598-1604.

32. Piccini J.P., Hasselblad V., Peterson E.D. et al. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J. Am. Coll. Cardiol., 2009, vol. 54, pp. 1089-1095.

33. Pisters R., Lane D.A., Nieuwlaat R. et al. A novel user-friendly score (HAS– BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest, 2010, vol. 138, pp. 1093-1100.

34. Pokushalov E., Romanov A., Artyomenko S. et al. Circulation: arrhythmia and electrophysiology. 2011, vol. 4, no. 6, pp. 823-831.

35. Sakamoto A., Kitakaze M., Takamoto S. et al. Landiolol, an ultra-short-acting β1-blocker, more effectively terminates atrial fibrillation than diltiazem after open heart surgery: prospective, multicenter, randomized, open-label study (JL-KNIGHT study). Circ. J., 2012, vol. 76, pp. 1097-1101.

36. Sasao J., Tarver S.D., Kindscher J.D. et al. In rabbits, landiolol, a new ultra-short-acting beta-blocker, exerts a more potent negative chronotropic effect and less effect on blood pressure than esmolol. Can. J. Anaesth., 2001, vol. 48, pp. 985-989.

37. Singh B.N., Singh S.N., Reda D.J. et al. Amiodarone versus sotalol for atrial fibrillation. N. Engl. J. Med., 2005, vol. 352, pp. 1861-1872.

38. Soucier R., Silverman D., Abordo M. et al. Propafenone versus ibutilide for post operative atrial fibrillation following cardiac surgery: Neither strategy improves outcomes compared to rate control alone (the PIPAF study). Med. Sci. Monit., 2003, vol. 9, pp. I19–I23.

39. Stanley T.O., Mackensen G.B., Grocott H.P. et al. Neurological outcome research group; care investigators of the duke heart center. The impact of post-operative atrial fibrillation on neurocognitive outcome after coronary artery bypass graft surgery. Anesth. Analg., 2002, vol. 94, pp. 290-295.

40. Tisdale J.E., Padhi I.D., Goldberg A.D. et al. A randomized, double-blind comparison of intravenous diltiazem and digoxin for atrial fibrillation after coronary artery bypass surgery. Am. Heart J., 1998, vol. 135, pp. 739-747.

41. Van de Werf F., Brueckmann M., Connolly S.J. et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE–ALIGN). Am. Heart J., 2012, vol. 163, pp. 931-937.

42. Ziegler P.D., Glotzer T.V., Daoud E.G. et al. Detection of previously undiagnosed atrial fibrillation in patients with stroke risk factors and usefulness of continuous monitoring. Am. J. Cardiol., 2012, www.ncbi.nim.nih.gov.pubmed

43. Ziegler P.D., Koehler J.L., Mehra R. Comparison of continuous versus intermittent monitoring of atrial arrhythmias. Heart Rhythm., 2006, vol. 3, pp. 1445-1452.